The effects of vitamin supplementation and MTHFR (C677T) genotype on homocysteine-lowering and migraine disability

Pharmacogenetics and Genomics

Volumn 19, Issue 6, 2009, Pages 422-428

  Lea, Rod ^a,c   Colson, Natalie ^a   Quinlan, Sharon ^a   MacMillan, John ^b   Griffiths, Lyn ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH   (New Zealand)

Author keywords

Homocysteine; Migraine; MTHFR genotype; Vitamin supplementation

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PLACEBO; PYRIDOXINE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2);

ADULT; ALLELE; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; FEMALE; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; ONSET AGE; PAIN ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION; BLOOD; ENZYMOLOGY; GENETICS; MIDDLE AGED;

DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; HOMOCYSTEINE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MIGRAINE DISORDERS; VITAMIN B 12; VITAMIN B 6;

EID: 70149101206     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32832af5a3     Document Type: Article

References (29)

1. Headache Classification Committee of The International Headache Society. The International Classification of Headache Disorders (2nd edition). Cephalalgia 2004; 24 (Suppl 1):1-160.
2. Goadsby PJ. Current concepts of the pathophysiology of migraine. Neurol Clin 1997; 15:27-42.
3. Ferrari M. Migraine. Lancet 1998; 351:1043-1051.
4. Tzourio C, El Amrani M, Poirier O, Nicaud V, Bousser MG, Alperovitch A. Association between migraine and endothelin type A receptor (ETA-231 A/G) gene polymorphism. Neurology 2001; 56:1273-1277.
5. Harker LA, Ross R, Slichter SJ, Scott CR. Homocysteine-induced arteriosclerosis: the role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976; 58:731-741.
6. Wall RT, Harlan JM, Harker LA, Striker GE. Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res 1980; 18:113-121.
7. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, Loscalzo J. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993; 91:308-318.
8. Cooke JP, Tsao PS. Is NO an endogenous antiatherogenic molecule? Arterioscler Thromb 1994; 14:653-655.
9. Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY, Faraci FM, Malinow MR, et al. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest 1996; 98:24-29.
10. Hering-Hanit R, Gadoth N, Yavetz A, Gavendo S, Sela B. Is blood homocysteine elevated in migraine. Headache 2001; 41:779-781.
11. Bouassira D, Bars DL, Villanueva L. Heterotopic activation of A delta and C fibres triggers inhibition of trigeminal and spinal convergent neurones in the rat. J Physiol 1987; 389:301-317.
12. Storer RJ, Goadsby PJ. Microiontophoretic application of serotonin (5HT)1B/1D agonists inhibits trigeminal cell firing in the cat. Brain 1997; 120:2171-2177.
13. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002; 325:1202.
14. Tzourio C, Iglesias S, Hubert JB, Visy JM, Alperovitch A, Tehindrazanarivelo A, et al. Migraine and risk of ischaemic stroke: a case-control study. BMJ 1993; 307:289-292.
15. Merikangas KR, Fenton BT, Cheng SH, Stolar MJ, Risch N. Association between migraine and stroke in a large-scale epidemiological study of the United States. Arch Neurol 1997; 54:362-368.
16. Kurth T. Migraine and ischaemic vascular events. Cephalalgia 2007; 27:965-975.
17. Scher AI, Terwindt GM, Verschuren WM, Kruit MC, Blom HJ, Kowa H, et al. Migraine and MTHFR C677 T genotype in a population-based sample. Ann Neurol 2006; 59:372-375.
18. Silberstein SD. Shared mechanisms and comorbidities in neurologic and psychiatric disorders. Headache 2001; 41 (Suppl 1):S11-S17.
19. Wang X, Qin X, Demirtas H, Li J, Mao G, Huo Y, et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 2007; 369:1876-1882.
20. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10:111-113.
21. Rubino E, Ferrero M, Rainero I, Binello E, Vaula G, Pinessi L. Association of the C677T polymorphism in the MTHFR gene with migraine: a meta-analysis. Cephalalgia 2007; 27:1199-1320.
22. Tfelt-Hansen P, Block G, Dahlof C, Diener H-C, Ferrari MD, Goadsby PJ, et al. Guidelines for controlled trials of drugs in migraine: 2nd edition. Cephalalgia 2000; 20:765-786.
23. Stewart WF, Lipton RB, Whyte J, Dowson A, Kolodner K, Liberman JN, Sawyer J. An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology 1999; 53:988-994. (Pubitemid 29442114)
24. Stewart WF, Lipton RB, Kolodner K, Liberman J, Sawyer J. Reliability of the migraine disability assessment score in a population-based sample of headache sufferers. Cephalalgia 1999; 19:107-114. (Pubitemid 29170106)
25. Lea RA, Ovcaric M, Sundholm J, MacMillan J, Griffiths LR. The methylenetetrahydrofolate reductase gene variant C677T influences susceptibility to migraine with aura. BMC Med 2004; 2:3.
26. Selhub J, Jacques PF, Rosenberg IH, Rogers G, Bowman BA, Gunter EW, et al. Serum total homocysteine concentrations in the third National Health and Nutrition Examination Survey (1991-1994): population reference ranges and contribution of vitamin status to high serum concentrations. Ann Intern Med 1999; 131:331-339.
27. Di Rosa G, Attinà S, Spanò M, Ingegneri G, Sgrò DL, Pustorino G, et al. Efficacy of folic acid in children with migraine, hyperhomocysteinemia and MTHFR polymorphisms. Headache 2007; 47:1342-1344.
28. Ho GY, Eikelboom JW, Hankey GJ, Wong CR, Tan SL, Chan JB, Chen CP. Methylenetetrahydrofolate reductase polymorphisms and homocysteine-lowering effect of vitamin therapy in Singaporean stroke patients. Stroke 2006; 37:456-460.
29. Kopjas TL. The use of folic acid in vascular headache of the migraine type. Headache 1969; 8:167-170.